Search

Your search keyword '"Carson, W.E."' showing total 21 results
Start Over Author "Carson, W.E."
21 results on '"Carson, W.E."'

1. EP14.05-004 Temozolomide and Atezolizumab as Second Line Treatment for Extensive Stage Small Cell Lung Cancer: A Randomized, Multi-Cohort Phase 2 Trial

Author

Owen, D.H., primary, Durm, G.A., additional, Wei, L., additional, Pilcher, C., additional, Ferguson, S., additional, Benner, B., additional, Jukich, M., additional, Sukrithan, V., additional, Konda, B., additional, Savardekar, H., additional, Spakowicz, D., additional, Schwarz, E., additional, Norman, R.O., additional, Wesolowski, R., additional, Carson, W.E., additional, Kaufman, J., additional, Alahmadi, A., additional, Memmott, R., additional, Shields, P., additional, He, K., additional, Bertino, E.M., additional, Presley, C.J., additional, Carbone, D.P., additional, and Otterson, G.A., additional

Published
2022
Full Text
View/download PDF

2. OA12.04 Efficacy of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer after Chemo-Immunotherapy: A Phase 2 Trial.

Author

Owen, D.H., primary, Wei, L., additional, Benner, B., additional, Pilcher, C., additional, Christenson, G., additional, Ferguson, S., additional, Jukich, M., additional, Sukrithan, V., additional, Konda, B., additional, Shah, M., additional, Savardekar, H., additional, Schwarz, E., additional, Norman, R.O., additional, Wesolowski, R., additional, Carson, W.E., additional, Kaufman, J., additional, Alahmadi, A., additional, Memmott, R., additional, Shields, P., additional, He, K., additional, Bertino, E.M., additional, Presley, C.J., additional, Carbone, D.P., additional, Verschraegen, C., additional, and Otterson, G.A., additional

Published
2022
Full Text
View/download PDF

6. Defining the Critical Hurdles in Cancer Immunotherapy

Author

Fox, B.A., Schendel, D.J., Butterfield, L.H., Aamdal, S., Allison, J.P., Ascierto, P.A., Atkins, M.B., Bartunkova, J., Bergmann, L., Berinstein, N., Bonorino, C.C., Borden, E., Bramson, J.L., Britten, C.M., Cao, X., Carson, W.E., Chang, A.E., Characiejus, D., Choudhury, A., Coukos, G., Gruijl, T.D. de, Dillman, R.O., and Dolstra, H.

Subjects
Immune Regulation Translational research [NCMLS 2], GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract

Contains fulltext : 97787.pdf (Publisher’s version ) (Open Access)

Published
2011

8. Defining the Critical Hurdles in Cancer Immunotherapy

Author

Fox, BA, Schendel, D.J., Butterfield, L.H., Aamdal, S., Allison, J.P., Ascierto, P.A., Atkins, M.B., Bartunkova, J., Bergmann, L., Berinstein, N., Bonorino, C.C., Borden, E., Bramson, J.L., Britten, C.M., Cao, X., Carson, W.E., Chang, A.E., Characiejus, D., Choudhury, A.R., Coukos, G., de Gruijl, T.D., Dillman, R.O., Dolstra, H., Dranoff, G., Durrant, L.G., Finke, J.H., Galon, J., Gollob, J.A., Gouttefangeas, C., Grizzi, F., Guida, M., Hakansson, L., Hege, K., Herberman, R.B., Hodi, F.S., Hoos, A., Huber, C., Hwu, P., Imai, K., Jaffee, E.M., Janetzki, S., June, C.H., Kalinski, P., Kaufmann, H.L., Kawakami, K., Kawakami, Y., Keilholtz, U., Khleif, S.N., Kiessling, R., Kotlan, B., Kroemer, G., Lapointe, R., Levitsky, H.I., Lotze, M.T., Di Maio, M., Marschner, J.P., Mastrangelo, M.J., Masucci, G., Melero, I., Nelief, C., Murphy, W.J., Nelson, B., Nicolini, A., Nishimura, M.I., Odunsi, K., Ohashi, P.S., O'Donnell-Tormey, J., Old, L.J., Ottensmeier, C., Papamichail, M., Parmiani, G., Pawelec, G., Proietti, E., Qin, S., Rees, R., Ribas, A., Ridolfi, R., Ritter, G., Rivoltini, L., Romero, P.J., Salem, M.L., Scheper, R.J., Seliger, B., Sharma, P., Shiku, H., Singh-Jasuja, H., Song, W., Straten, P.T., Tahara, H., Tian, Z., van der Burg, S.H., von Hoegen, P., Wang, E., Welters, M.J., Winter, H., Withington, T., Wolchok, J.D., Xiao, W., Zitvogel, L., Zwierzina, H., Marincola, F.M., Gajewski, T.F., Wigginton, J.M., Disis, M.L.A., Fox, BA, Schendel, D.J., Butterfield, L.H., Aamdal, S., Allison, J.P., Ascierto, P.A., Atkins, M.B., Bartunkova, J., Bergmann, L., Berinstein, N., Bonorino, C.C., Borden, E., Bramson, J.L., Britten, C.M., Cao, X., Carson, W.E., Chang, A.E., Characiejus, D., Choudhury, A.R., Coukos, G., de Gruijl, T.D., Dillman, R.O., Dolstra, H., Dranoff, G., Durrant, L.G., Finke, J.H., Galon, J., Gollob, J.A., Gouttefangeas, C., Grizzi, F., Guida, M., Hakansson, L., Hege, K., Herberman, R.B., Hodi, F.S., Hoos, A., Huber, C., Hwu, P., Imai, K., Jaffee, E.M., Janetzki, S., June, C.H., Kalinski, P., Kaufmann, H.L., Kawakami, K., Kawakami, Y., Keilholtz, U., Khleif, S.N., Kiessling, R., Kotlan, B., Kroemer, G., Lapointe, R., Levitsky, H.I., Lotze, M.T., Di Maio, M., Marschner, J.P., Mastrangelo, M.J., Masucci, G., Melero, I., Nelief, C., Murphy, W.J., Nelson, B., Nicolini, A., Nishimura, M.I., Odunsi, K., Ohashi, P.S., O'Donnell-Tormey, J., Old, L.J., Ottensmeier, C., Papamichail, M., Parmiani, G., Pawelec, G., Proietti, E., Qin, S., Rees, R., Ribas, A., Ridolfi, R., Ritter, G., Rivoltini, L., Romero, P.J., Salem, M.L., Scheper, R.J., Seliger, B., Sharma, P., Shiku, H., Singh-Jasuja, H., Song, W., Straten, P.T., Tahara, H., Tian, Z., van der Burg, S.H., von Hoegen, P., Wang, E., Welters, M.J., Winter, H., Withington, T., Wolchok, J.D., Xiao, W., Zitvogel, L., Zwierzina, H., Marincola, F.M., Gajewski, T.F., Wigginton, J.M., and Disis, M.L.A.

Abstract

Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer. © 2011 Fox et al; licensee BioMed Central Ltd.

Published
2011
Full Text
View/download PDF

9. 15. Attachment anxiety is related to Epstein–Barr virus latency while undergoing testing for breast or colon cancer, as well as one year later

Author

Fagundes, C.P., primary, Jaremka, L.M., additional, Glaser, R., additional, Alfano, C.M., additional, Povoski, S.P., additional, Lipari, A.M., additional, Agnese, D.M., additional, Yee, L.D., additional, Carson, W.E., additional, Farrar, W.B., additional, Malarkey, W.B., additional, Chen, M., additional, and Kiecolt-Glaser, J.K., additional

Published
2013
Full Text
View/download PDF

12. 118. Social support and socioeconomic status interact to predict Epstein-Barr virus latency in women awaiting diagnosis or newly diagnosed with breast cancer

Author

Fagundes, C.P., primary, Bennett, J.M., additional, Alfano, C.M., additional, Glaser, R., additional, Povoski, S.P., additional, Lipari, A.M., additional, Agnese, D.M., additional, Yee, L.D., additional, Carson, W.E., additional, Farrar, W.B., additional, Malarkey, W.B., additional, Chen, M., additional, and Kiecolt-Glaser, J.K., additional

Published
2011
Full Text
View/download PDF

16. 109

Author

Carson, W.E., primary and Jones, N.B., additional

Published
2007
Full Text
View/download PDF

20. Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo

Author

Fehniger, T.A., Carson, W.E., Mrozek, E., and Caligiuri, M.A.

Subjects
Interleukin-2 -- Health aspects -- Physiological aspects, Killer cells -- Physiological aspects -- Health aspects, Health, Physiological aspects, Health aspects
Abstract

'Stem Cell Factor Enhances Interleukin-2-Mediated Expansion of Murine Natural Killer Cells in vivo.' Blood, November 1, 1997;90(9):3647-3653. According to the authors' abstract of an article published in Blood, 'The administration [...]

Published
1997

Catalog

Books, media, physical & digital resources
See catalog results